InVivo Therapeutics (NVIV.OB +19.9%) rises sharply on heavy volume after announcing the FDA has...


InVivo Therapeutics (NVIV.OB +19.9%) rises sharply on heavy volume after announcing the FDA has approved its request for a Humanitarian Use Device designation for its biopolymer scaffolding product. The designation should help the company speed the product to market. A clinical trial submission is being reviewed by the FDA currently. 

Comments (1)
  • Special_Sit
    , contributor
    Comments (166) | Send Message
     
    Next catalysts:
    a) Commence clinical trial (I anticipate before end of this month)
    b) First patient treated (2013)
    c) Clinical outcomes of first several treated patients (open-label study)
    d) File IND or equivalent for hydrogel by year-end
    e) Announce partnership / licensing agreement by year-end
    f) Publication of NHP study
    g) Filing for BSD approval (1H2014)
    g) Oral presentation of clinical trial results (1H 2014)

     

    Two more predictions:
    -Average volume picks up substantially, price goes > $4/share, drawing larger investors, driving shares even higher in 2013.
    -Stock trades $5/sh or better in 2014
    5 Apr 2013, 10:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs